At its 13th plenary meeting, held on february 13-15 at the European Medicines Evaluation Agency, the European Commission's Committee for Proprietary Medicinal Products:
- adopted positive opinions by consensus for four medicinal products corresponding to three new substances under the centralized procedure, including three submitted during 1995. These opinions will be forwarded to the Commission shortly;
- adopted by consensus a positive opinion for the first application for a type II variation procedure for a recent European Marketing Authorization. Positive opinions for 13 new medicinal products (four from new centralized procedures and nine from ex-concertation procedures) have been adopted by consensus since May 1995. The Committee also noted that the Commission has now granted EMAs to Schering-Plough's Fareston (toremifene) and Roche's Cellcept (mycophenolate mofetil); see also page 21;
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze